EU/3/19/2140

Table of contents

About

On 26 February 2019, orphan designation (EU/3/19/2140) was granted by the European Commission to Artemida Pharma Europe Limited, Ireland, for humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase (also known as JR-141) for the treatment of mucopolysaccharidosis type II (Hunter’s syndrome).

Key facts

Active substance
Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase
Disease / condition
Treatment of mucopolysaccharidosis type II (Hunter’s syndrome)
Date of decision
26/02/2019
Outcome
Positive
Orphan decision number
EU/3/19/2140

Sponsor's contact details

Artemida Pharma Europe Limited
The Black Church
Saint Mary's Place North
Dublin 7 D07 P4AX
Ireland
Tel. +353 1437 2313
E-mail: artemida@artemidapharma.com

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating